This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXMPED2T082_M.jpg
After-Hours Movers:
CytomX Therapeutics, Inc. (NASDAQ:CTMX) 52% HIGHER; The company and Moderna (NASDAQ:MRNA) announced a collaboration and licensing agreement to create investigational mRNA-based conditionally activated therapies utilizing Moderna’s mRNA technologies and CytomX’s Probody therapeutic platform.
Fate Therapeutics, Inc. (NASDAQ:FATE) 50% LOWER; declined a proposal from Janssen Biotech, Inc. (Janssen) for a continuation of the collaboration and option agreement between the parties on revised terms and conditions and, as a result, the agreement has been terminated and all collaboration activities will be wound down in the first quarter of 2023. In addition, the Company has completed a strategic review of its natural killer (NK) cell product pipeline and has elected to focus on advancing its most innovative and differentiated programs, which have a multiplexed-engineered cellular framework of novel synthetic controls designed to promote multi-antigen targeting, increase potency, extend functional persistence, and enable patient dosing with reduced conditioning chemotherapy.
Graphite Bio Inc (NASDAQ:GRPH) 45% LOWER; announced it is voluntarily pausing the Phase 1/2 CEDAR study of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease (SCD) due to a serious adverse event in the first patient dosed with nula-cel, and the companys conclusion that the event is likely related to study treatment. As a result, the company will not meet its guidance for initial proof-of-concept data in mid-2023.
World Wrestling Entertainment (NYSE:WWE) 11% HIGHER; Vince McMahon to return, expressed willingness to explore a sale.
Costco Wholesale Corporation (NASDAQ:COST) 3% HIGHER; December comps rose 5.5%, or 7.3% ex-gas and forex.
